Skip to content
Open access

The Association of Early Graft Dysfunction and CYP3A5 Genotype With Tacrolimus Exposure in Adult Kidney Transplant Recipients

Nov 2026 · Pharmacotherapy · Vol 46 · 0 citations · 15 references
Medicine

TL;DR

Investigation of the interplay between early graft function and pharmacogenetics on tacrolimus dose requirements in adult kidney transplant recipients found patients with early graft dysfunction who were CYP3A5 nonexpressers had the highest tacrolimus exposure.

Abstract

ABSTRACT Introduction The incidence of early graft dysfunction following kidney transplantation is rising due to the expanded use of marginal organs. Prior studies have suggested that acute kidney dysfunction causes renohepatic crosstalk and tacrolimus metabolism may be decreased. It is also well known that tacrolimus metabolism and dosing requirements differ significantly based on a recipient's CYP3A5 genotype. The objective of this study was to investigate the interplay between early graft function and pharmacogenetics on tacrolimus dose requirements in adult kidney transplant recipients. Methods This was a single‐center, retrospective cohort study of adult kidney transplant recipients who received immediate‐release tacrolimus and had CYP3A5 genotypes available. Immediate graft function (IGF) was defined as serum creatinine decrease of ≥ 10% from baseline and urine output ≥ 0.5 mL/kg/h on post‐operative day (POD) 1. Tacrolimus dose‐normalized trough concentration (C/D) on POD 2 was compared between patients with IGF and non‐IGF using Mann–Whitney U test. Patients were then grouped by both IGF and CYP3A5 genotype, and the differences in C/D considering these factors were analyzed by Mann Whitney U test and a multivariable linear regression analysis. Results A total of 242 patients were included, 185 with IGF and 57 with non‐IGF. The median [IQR: interquartile range] of tacrolimus C/D was higher in non‐IGF than IGF (200.0 [129.7–327.1] vs. 134.0 [95.0–197.4] [ng/ml]/[mg/kg/day], p < 0.001). Among CYP3A5 nonexpressers, the median [IQR] of tacrolimus C/D was 73% higher in non‐IGF than IGF (263.3 [177.5–390.1] vs. 151.8 [105.1–214.1] [ng/ml]/[mg/kg/day], p < 0.001), and 16% higher in CYP3A5 expressers with non‐IGF versus IGF (116.2 [102.3–199.5] vs. 101.1 [72.5–131.0] [ng/ml]/[mg/kg/day], p = 0.01). In the multivariable linear regression model, the effects of IGF and CYP3A5 expression on tacrolimus C/D remained significant. Conclusion Patients with early graft dysfunction who were CYP3A5 nonexpressers had the highest tacrolimus exposure. Initial tacrolimus dose reductions may be considered in kidney transplant recipients who are at risk for non‐IGF, especially in CYP3A5 nonexpressers.

Read PDF

Similar papers

Open access Oct 2026

The impact of tacrolimus variability on first year renal function in kidney transplant recipients

High variability was associated with more frequent subtherapeutic and supratherapeutic trough concentrations and transient reductions in early graft performance and 12-month eGFR was not significantly different between variability groups, however, 12-month eGFR was not significantly different between variability groups...

Ferah Taran, E. Turkmen · 0 citations
Open access Nov 2026

Association of graft survival with tacrolimus metabolism in pediatric and young adult kidney transplant recipients: an international Collaborative Transplant Study analysis.

INTRODUCTION Evidence on the association between tacrolimus concentration-to-dose ratio (CDR), a surrogate marker of tacrolimus metabolism, and graft outcome in pediatric and young adult kidney transplant recipients is limited. METHODS We retrospectively analyzed 3768 pediatric (1-17 years old) and young adult (18-24...

M. Baghai Arassi, B. Döhler, B. Tönshoff et al. · 0 citations
Oct 2026

Population Pharmacokinetic Analysis of Tacrolimus in Time‐Dependent Increase of Clearance for Patients with Living‐Donor Liver Transplantation: A Prospective Observational Study

Tacrolimus is a first‐line immunosuppressant used to prevent rejection in living donor liver transplantation (LDLT) and is subject to therapeutic drug monitoring due to its concentration‐dependent effects and side effects. Metabolism of tacrolimus is reduced by the CYP3A5*3 allele. In addition, liver regeneration over...

Naoya Matsumoto, Kazutaka Oda, K. Shimata et al. · 0 citations
Oct 2026

Evaluation of CYP3A Phenoconversion in Immunosuppressed Patients Following Kidney Transplantation.

BACKGROUND Tacrolimus, featuring a narrow therapeutic index, is key in post-kidney transplant immunosuppression. Changes in CYP3A enzyme expression may complicate achieving therapeutic tacrolimus concentrations. This study investigated factors contributing to CYP3A phenoconversion. METHODS Data from 24 kidney transpl...

B. Nemes, Gyula Erdélyi, Tímea Silye-Cseh et al. · 0 citations
Open access Jan 2026

Effects of Timing of Everolimus Transition on Renal Outcomes in Liver Transplant Recipients

Introduction Everolimus is often used in liver transplant recipients to minimize calcineurin inhibitors and their associated renal toxicity. This study aimed to evaluate the effects of the timing of everolimus transition on renal outcomes in adult liver transplant recipients. Materials and Methods This retrospective su...

M. Leick, Hannah Belleau, T. McCashland · 0 citations
Open access Oct 2026

EFFECT OF GENOTYPE- AND THERAPEUTIC DRUG MONITORING-GUIDED TACROLIMUS DOSING IN RENAL TRANSPLANT RECIPIENTS WITH EXTENSIVE METABOLISM

Objectives: The aim of this study was to evaluate the effect of genotype- and therapeutic drug monitoring (TDM)-guided tacrolimus dosing in renal transplant recipients with extensive metabolism. Methods: This prospective observational study included 34 renal transplant recipients identified as extensive metabolizers fr...

Ratheeshkumar Nm, Rajan Kumar, Feroz Aziz et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.